The role of decorin and biglycan signaling in tumorigenesis
- The complex and adaptive nature of malignant neoplasm constitute a major challenge for the development of effective anti-oncogenic therapies. Emerging evidence has uncovered the pivotal functions exerted by the small leucine-rich proteoglycans, decorin and biglycan, in affecting tumor growth and progression. In their soluble forms, decorin and biglycan act as powerful signaling molecules. By receptor-mediated signal transduction, both proteoglycans modulate key processes vital for tumor initiation and progression, such as autophagy, inflammation, cell-cycle, apoptosis, and angiogenesis. Despite of their structural homology, these two proteoglycans interact with distinct cell surface receptors and thus modulate distinct signaling pathways that ultimately affect cancer development. In this review, we summarize growing evidence for the complex roles of decorin and biglycan signaling in tumor biology and address potential novel therapeutic implications.
Author: | Valentina DiehlGND, Lisa Sophie Huber, Jonel TrebickaORCiDGND, Małgorzata WygreckaORCiDGND, Renato V. IozzoORCiDGND, Liliana SchäferORCiD |
---|---|
URN: | urn:nbn:de:hebis:30:3-620587 |
DOI: | https://doi.org/10.3389/fonc.2021.801801 |
ISSN: | 2234-943X |
Parent Title (English): | Frontiers in oncology |
Publisher: | Frontiers Media |
Place of publication: | Lausanne |
Document Type: | Article |
Language: | English |
Date of Publication (online): | 2021/11/30 |
Date of first Publication: | 2021/11/30 |
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
Release Date: | 2024/04/24 |
Tag: | angiogenesis; autophagy; cancer; extracellular matrix; inflammation; proteoglycan; toll-like receptor |
Volume: | 11 |
Issue: | art. 801801 |
Article Number: | 801801 |
Page Number: | 17 |
First Page: | 1 |
Last Page: | 17 |
Note: | The authors’ laboratories were supported by the German Research Council (SFB 1039, project B02, SFB 1177, 259130777, project E02, all to LS; and the CardioPulmonary Institute (CPI), EXC 2026, Project ID: 390649896 (to LS and MW); WY119/1-3 (to MW), the Else Kroner-Fresenius-Foundation (to MW), and the German Center for Lung Research (to MW);¨ European Union’s Horizon 2020 research and innovation program’s MICROBPREDICT study (No 825694), European Union’s Horizon 2020 Research and Innovation Program GALAXY (No. 668031) and Societal Challenges LIVERHOPE (Health, demographic change, and well-being, No. 731875) the German Research Council (SFB TRR57, CRC1382), Cellex Foundation (PREDICT) all to JT. The original research in Dr. Iozzo laboratory was supported in part by National Institutes of Health Grants RO1 CA39481 and RO1 CA245311. |
HeBIS-PPN: | 521043379 |
Institutes: | Medizin |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Sammlungen: | Universitätspublikationen |
Licence (German): | Creative Commons - CC BY - Namensnennung 4.0 International |